#4 - Johnson & Johnson (NYSE:JNJ)
In January 2022, Johnson & Johnson (NYSE:JNJ) made a list of stocks to buy from Goldman Sachs (NYSE:GS). The sole criteria were to find stocks that had showcased pricing power over the last five years. This isn’t a surprise to investors in JNJ stock, who have been rewarded with a workmanlike 34% gain over that same span.
The company has a portfolio of products that are essential for many consumers. But many investors may be surprised at the expanse of the company’s portfolio, which includes pharmaceutical products as well as the medical technology (Medtech) sectors.
Johnson & Johnson is the second dividend king on this list. The company has increased its dividend every year for the last 61 years. As of July 2022, it has a dividend payout ratio of over 60%. That suggests that investors should have no cause for concern that the company will continue to increase its dividend over time.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
More about Johnson & Johnson- Current Price
- $153.03
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $171.33 (12.0% Upside)
